- Featured News /
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
- Featured News /
Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world. - Featured News /
Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.
- Featured News /
Novartis included in Dow Jones Sustainability World Index, with industry-leading performance in environmental and social reporting and human capital.
- Featured News /
September 29 is World Heart Day. For the past six decades, Novartis has been working to advance heart health around the world.
- Featured News /
European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.
- Featured News /
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.
- Featured News /
Driven by our passion for patients and grounded in our industry-leading pipeline of 45+ different compounds across 70+ development programs, Novartis is rapidly advancing novel cancer treatment approaches in areas of great medical need.
- Featured News /
Together in spirit. Find out how our associates all over the world are joining together to make a difference as we celebrate Pride 2020.
- Featured News /
Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.
Pagination
- ‹ Previous page
- 1
- …
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- …
- 277
- › Next page